Free Trial
NASDAQ:GYRE

Gyre Therapeutics Q2 2025 Earnings Report

Gyre Therapeutics logo
$7.07 -0.12 (-1.67%)
Closing price 04:00 PM Eastern
Extended Trading
$6.92 -0.15 (-2.18%)
As of 06:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gyre Therapeutics EPS Results

Actual EPS
$0.02
Consensus EPS
$0.03
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Gyre Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$30.80 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Gyre Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, August 11, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Gyre Therapeutics' Q3 2025 earnings is scheduled for Tuesday, August 12, 2025

Gyre Therapeutics Earnings Headlines

Gyre Therapeutics CEO Departs
Man Who Called Nvidia at $1.10 Says Buy This Now...
In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.
Gyre Therapeutics (GYRE) Projected to Post Quarterly Earnings on Tuesday
See More Gyre Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gyre Therapeutics and other key companies, straight to your email.

About Gyre Therapeutics

Gyre Therapeutics (NASDAQ:GYRE), a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

View Gyre Therapeutics Profile

More Earnings Resources from MarketBeat